Cumulative Q3 sales for FY2026 were 21.19 billion yen, a 4.7% decrease YoY, with operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast was revised downward, projecting sales of 30.69 billion yen and operating income of 2.60 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Biomedical Laboratories, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/2395-20260206-03.pdf","jir_short_summary":"Cumulative Q3 sales for FY2026 were 21.19 billion yen, a 4.7% decrease YoY, with operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast was revised downward, projecting sales of 30.69 billion yen and operating income of 2.60 billion yen.","jir_summary":"### Performance Overview\nCumulative sales for the third quarter of FY ending March 2026 amounted to 21.19 billion yen, a 4.7% decrease YoY, with operating income at 1.02 billion yen, down 46.1% YoY. The primary reasons were a delay in sales recognition for large studies in the Nonclinical CRO business to the fourth quarter and increased operating losses due to a 560 million yen expense booked by Satsuma Co. Increased depreciation from capital investments also pressured profits. However, orders from European and American customers in the Nonclinical CRO business remained solid, with Q3 order intake reaching 10.0 billion yen, a record high with a 13.7% YoY increase.\n\n### Full-Year Outlook and Future Direction\nThe full-year earnings forecast was revised downward to sales of 30.69 billion yen, operating income of 2.60 billion yen, ordinary income of 5.35 billion yen, and net income attributable to owners of the parent of 3.56 billion yen. The main factors were the second half expense recognition of 1.24 billion yen for Satsuma Co. and a shift in sales recognition timing in the Nonclinical CRO business. Conversely, the TR business is expected to contain operating profit downward revisions through expense control. The Nonclinical CRO business has also signed new preferred contracts with major pharmaceutical companies domestically and abroad, continuing efforts to secure contracts in Q4.","jir_financial_highlights":"Sales: 21.19 billion yen (4.7% decrease YoY)\nOperating Income: 1.02 billion yen (46.1% decrease YoY)\nOrdinary Income: 3.11 billion yen (24.7% decrease YoY)\nNet Income Attributable to Owners of Parent: 2.27 billion yen (29.2% decrease YoY)\nNonclinical CRO Business Q3 Order Intake: 10.0 billion yen (13.7% increase YoY)\nFull-Year Earnings Forecast Sales: 30.69 billion yen (7.7% decrease from initial forecast)\nFull-Year Earnings Forecast Operating Income: 2.60 billion yen (26.8% decrease from initial forecast)","jir_category":"","jir_hashtags":"#ShinNipponBiomedical, #FinancialResultsPresentation, #JapaneseStocks","jir_key_figures":"Cumulative Q3 Sales: 21.19 billion yen (4.7% decrease YoY)\nCumulative Q3 Operating Income: 1.02 billion yen (46.1% decrease YoY)\nFull-Year Sales Forecast: 30.69 billion yen (7.7% decrease from initial forecast)","jir_meta_title":"Shin Nippon Biomedical FY2026 Q3 Financial Results: Sales Decline to 21.19 Billion Yen, Operating Income Falls to 1.02 Billion Yen","jir_meta_description":"Shin Nippon Biomedical's FY2026 Q3 financial results show sales of 21.19 billion yen, down 4.7% YoY, and operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast has been revised downward, projecting sales of 30.69 billion yen and operating income of 2.60 billion yen.","jir_og_title":"Shin Nippon Biomedical Announces FY2026 Q3 Financial Results","jir_og_description":"Sales at 21.19 billion yen and operating income at 1.02 billion yen. Despite increased orders in the Nonclinical CRO business, the full-year outlook was revised downward due to delays in revenue recognition for large studies.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cumulative Q3 Order Intake Trends from North American and European Customers\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY3\/22 Cumulative Q3\\\",\\\"FY3\/23 Cumulative Q3\\\",\\\"FY3\/24 Cumulative Q3\\\",\\\"FY3\/25 Cumulative Q3\\\",\\\"FY3\/26 Cumulative Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Order Intake (Million Yen)\\\",\\\"data\\\":[3897,4817,4318,6478,10137],\\\"backgroundColor\\\":\\\"#4CAF50\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"order_balance_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Order Backlog Trends as of Q3 End (December End) for North American and European Customers\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY3\/22 Q3 End\\\",\\\"FY3\/23 Q3 End\\\",\\\"FY3\/24 Q3 End\\\",\\\"FY3\/25 Q3 End\\\",\\\"FY3\/26 Q3 End\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Order Backlog (Million Yen)\\\",\\\"data\\\":[5082,7846,8504,11266,17760],\\\"backgroundColor\\\":\\\"#2196F3\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"investment_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Trends in Capital Investment and Depreciation Expenses\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY3\/21\\\",\\\"FY3\/22\\\",\\\"FY3\/23\\\",\\\"FY3\/24\\\",\\\"FY3\/25\\\",\\\"FY3\/26 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Capital Investment (100 Million Yen)\\\",\\\"data\\\":[10.3,17.0,56.1,85.2,113.9,61.9],\\\"backgroundColor\\\":\\\"#B0BEC5\\\"},{\\\"label\\\":\\\"Depreciation Expense (100 Million Yen)\\\",\\\"data\\\":[11.9,11.8,15.4,17.7,24.9,30.9],\\\"backgroundColor\\\":\\\"#0D47A1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"financial_summary_q3\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"FY2026 Q3 Financial Highlights\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"headers\\\":[\\\"Metric\\\",\\\"FY2025 Cumulative Q3 Actual\\\",\\\"FY2026 Cumulative Q3 Actual\\\",\\\"YoY Change\\\"],\\\"rows\\\":[[\\\"Sales\\\",\\\"22.23 billion yen\\\",\\\"21.19 billion yen\\\",\\\"-4.7%\\\"],[\\\"Operating Income\\\",\\\"1.89 billion yen\\\",\\\"1.02 billion yen\\\",\\\"-46.1%\\\"],[\\\"Ordinary Income\\\",\\\"4.13 billion yen\\\",\\\"3.11 billion yen\\\",\\\"-24.7%\\\"],[\\\"Net Income Attributable to Owners of Parent\\\",\\\"3.20 billion yen\\\",\\\"2.27 billion yen\\\",\\\"-29.2%\\\"]]}}\"}, {\"jir_chart_id\": \"segment_performance\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2026 Q3 Segment Performance Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Sales\\\",\\\"Operating Income\\\",\\\"Operating Margin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"CRO Business FY2023 Cumulative Q3\\\",\\\"data\\\":[17483,4342,24.8],\\\"backgroundColor\\\":\\\"#4CAF50\\\"},{\\\"label\\\":\\\"CRO Business FY2024 Cumulative Q3\\\",\\\"data\\\":[21678,5146,23.7],\\\"backgroundColor\\\":\\\"#81C784\\\"},{\\\"label\\\":\\\"CRO Business FY2025 Cumulative Q3\\\",\\\"data\\\":[20257,4089,20.2],\\\"backgroundColor\\\":\\\"#388E3C\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24965","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n